ALK gene

The FDA ( US Food and Drug Administration ) has approved Tepmetko ( Tepotinib ) for the treatment of adult...


The FDA ( U.S. Food and Drug Administration ) has approved the PD-1 inhibitor Libtayo ( Cemiplimab-rwlc; Cemiplimab ) for...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Yescarta ( Axicabtagene ciloleucel ) for...


The FDA ( U.S. Food and Drug Administration ) has approved supplemental New Drug Application ( sNDA ) for Lorbrena...


HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ( ATTR )...


Full positive results from the HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...


Researchers have retrospectively examined progression-free survival ( PFS ) and response by ALK fluorescence in-situ hybridization ( FISH ) status...


The FDA ( U.S. Food and Drug Administration ) has approved Alunbrig ( Brigatinib ) for adult patients with anaplastic...


The European Commission ( EC ) has extended the marketing authorization of Alunbrig ( Brigatinib ) to include use as...


Positive results from the randomized phase 2 ELEKTRA study of Soticlestat in children with Dravet syndrome ( DS ) or...


The FDA ( U.S. Food and Drug Administration ) has approved Tabrecta ( Capmatinib ) for the treatment of adult...



In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell...


NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib ( Rozlytrek ) is a...


Final, mature progression-free survival ( PFS ) from the global phase III ALEX study of Alectinib ( Alecensa ) vs...


Lorlatinib ( Lorviqua ) is a 3rd-generation ALK tyrosine kinase inhibitor ( TKI ) developed to penetrate the central nervous...


The U.S. Food and Drug Administration ( FDA ) has approved Retevmo ( Selpercatinib ) capsules to treat three...


The European Commission has granted conditional marketing authorisation for Rozlytrek ( Entrectinib ) for the treatment of adult and paediatric...


Ensartinib is a novel second-generation ALK tyrosine kinase inhibitor ( TKI ). In phase 1/2 studies, Ensartinib showed promising activity...